Live feed08:15:00·279dPRReleasevia QuantisnowMinovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by GrowthByQuantisnow·Wall Street's wire, on your screen.LPAA· Launch One Acquisition Corp.
